Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ChaC glutathione-specific gamma-glutamylcyclotransferase 2 (abbreviated CHAC2) is an enzyme that catalyzes the cleavage of glutathione (GSH) into 5-oxo-L-proline and cysteinyl-glycine, acting specifically on glutathione but not other gamma-glutamyl peptides[3][5]. CHAC2 is a cytosolic enzyme involved in maintaining glutathione homeostasis and is upregulated in response to endoplasmic reticulum stress, enhancing apoptotic pathways via glutathione depletion[1][3]. Structural studies identify CHAC2 as having a unique flexible loop involved in GSH specificity and enzymatic regulation[1]. Overexpression of CHAC2 has been linked to enhanced proliferation of cancer cells, and it may play a role in the progression of glutathione-related diseases such as cancer and glutathionuria[1][3][5]. The molecule is being investigated as a potential therapeutic target, particularly for diseases where manipulation of glutathione metabolism might be beneficial[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ChaC glutathione-specific gamma-glutamylcyclotransferase 2 (CHAC2).